Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Hovione warp-speeds Ligand’s excipient
by Rick Mullin
September 26, 2020
| A version of this story appeared in
Volume 98, Issue 37
Hovione has signed an agreement to significantly ramp up output of Ligand Pharmaceuticals’ Captisol, a chemically modified cyclodextrin that improves drugs’ solubility and stability. Gilead Sciences uses the excipient to formulate the COVID-19 treatment remdesivir. “Hovione will soon be producing per month the quantity it usually produces in one year,” Jean-Luc Herbeaux, its chief operating officer, says in a press release. Hovione is the sole producer of Captisol under a longstanding partnership with Ligand.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter